Late-Breaking Research: Chemistry

• LB021 · PDF Enhanced therapeutic efficacy of ApoA1-Anti CD99 antibody fusion protein for treatment of Ewing sarcoma HyungGyoo Kang, Bryon Upton, Jon Nagy, Timothy Triche
• LB022 · PDF Cutting-edge, drug-free targeted cancer therapeutic: Smart folate-conjugated copolymer intrinsically disables the YAP/TAZ-HIPPO oncoproteins and abrogates pancreatic cancer progression and metastasis Reza Bayat Mokhtari, Nicole Mendonza, Daniel Leon Moshe, Yunfan Li, Daniella Ghokasian, Razieh Salahandish, Narges Baluch, Myron R. Szewczuk
• LB023 · PDF Design of a ligand targeted radiotherapy for treatment of bone metastasis Losha D. Jung, Neel T. Parekh, Nithin R. S. Raj, Lauren K. Thompson, Philip S. Low
• LB025 · PDF DNA damage chemical inducers of proximity (DD-CIP) for targeted cancer therapy Tian Qiu, Yeuan Ting Lee, Brendan G. Dwyer, Yi Jer Tan, Ting Chen, Bryan A. Romero, Yanlan Wang, Jiehui Deng, Tinghu Zhang, Gerald R. Crabtree, Stephen M. Hinshaw, Kwok-Kin Wong, Nathanael S. Gray
• LB027 · PDF AI guided engineering of pH responsive antibodies enables tumor selective targeting and improves the therapeutic index Qilin Yu, Mingchen Chen, Ying Lu, Yuxi Wang
• LB028 LN019, a novel HER2-targeting affibody-drug conjugate, demonstrates superior antitumor efficacy compared to T-DXd in xenograft models Xuelin Xia, Ning Sun, Wei Huang, Zhigang Yan, Zhao Sun, Yong Liu, Wenming Li, Xiaobo Li, Xiaoxia Xia, Deyue Yan
• LB029 · PDF An integrated high-throughput assay for proliferative phenotypic and omics profiling of single tumor cells Shiska Raut, Karoliina Stefanius, Bryan Presley, Digant P. Dave
• LB030 · PDF Chemoproteomic discovery of allosteric covalent GSTO1 inhibitors reveals a previously unrecognized binding mode with anti-inflammatory activity Nan Chen, Fengying Zhang, Wenchao Lu
• LB031 · PDF Transcriptomic evaluation of a potent trifluoromethyl phenyl acetamide derivative for its anticancer effect Mohamed A. Eltokhy, Ahmed Ragab, Eman A. Fayed, Moustafa S. Abusaif, Aya Thabet, Yousry A. Ammar, Sahar Radwan, Sanjay Srivastava
• LB032 · PDF The natural compound KH617 reverses glioblastoma resistance to alkylating agents via MGMT modulation Chun-Jie Li, Xue Yang, Ling-Min Lin, Qiao-Xin Tang, Yun Feng, Yong Zhu, Man-Xi Zhao, Xiao Ke
• LB033 · PDF KH617 API manufacturing: A synthetic biology approach Yi Zhou, Jiong-Qin Liu, Cheng-Guo Gao, Hao Luo, Man-Xi Zhao, Xiao Ke
• LB034 · PDF Broad-spectrum antitumor activity of the biosynthetically derived molecule KHN705 Yun Feng, Wang-Wei Mao, Yu-Jie Yuan, Hong Chen, Qiao-Xin Tang, Yong Zhu, Hao Luo, Man-Xi Zhao, Xiao Ke
• LB035 · PDF The natural compound KH617: A safe and selective therapeutic agent targeting GBM metabolic reprogramming Chun-Jie Li, Xue Yang, Li-Tao Liu, Yun Feng, Ling-Min Lin, Qiao-Xin Tang, Yong Zhu, Man-Xi Zhao, Zhuang Kang, Wen-Bin Li, Xiao Ke
• LB036 · PDF Characterization of BLU-448: A potent and selective degrader of CDK4 for the treatment of HR+/HER2- breast cancers Zhihu (Jeff) Ding*, Xiang Liu*, Barbara K. Robens, Jeff Keats, Suzanne Spong, Fereidoon Daryaee, Michael R. Wasserman, Benjamin Barlock, Jian Guo, James Baker, Kenneth Kearney, Gramoz Kondakci, Camila Medrano-Trochez, Christophe Lemetre, Emily Erickson, Hana von der Linden, Dean Zhang, Sheng Sun, Rentian Wu, Lakshimi Muthuswamy, Jie Ge, Luis Torres, Kevin Barvian, Thiwanka Mudiyanselage, Winston L. Chow, Deborah G. Conrady, Yunxing (Stella) Li, Xavier Fradera, Yinghui Dai, Caitlin Kinkema, Jason Brubaker, Robert Meissner, Thomas A. Dineen, Chiara Conti, Kerrie Faia, Scott Ribich
• LB037 · PDF A systematic mass spectrometry-based chemoproteomic platform (chomiXdegrade TM ) for molecular glue degrade discovery and mechanistic dissection Nan Chen, Fengying Zhang, Xin Yuan, Hao Hu
• LB038 · PDF Preclinical evaluation of a novel orally bioavailable MDM2 PROTAC, NW-8-461, in acute leukemia and myelofibrosis Qinhong Zhang, Yajing Xu, Qiong Wu, Cecilia Z. Tu, Shijia Wang, Kai Yin, Xuesong Xu, Zhang Zhang, Bing Dai, Fenlai Tan, Yi Chen
• LB039 · PDF Orally bioavailable BCL6 degrader HSK47977 featuring a novel CRBN ligand demonstrates potent antitumor activity and synergy with BCL2 inhibition in NHL Jun Xu, Qingyuan Meng, Yuting Liao, Chen Zhang, Jing Wei, Ruofeng Tang, Caixia Dou, Jie Yang, Pingming Tang, Zhen Chen, Yao Lu, Ju Wang, Pangke Yan
• LB040 · PDF Identification of a potent and selective PPIL4 degrader with therapeutic potential from a library of Cereblon modulators Yunchao Chang, Vanshita Goel, Gisele Nishiguchi, Vyoma Sheth, Zhe Shi, Pankaj Ghate, Joy Mondal, Irin Tom, Xiaoming Zhong, Kevin McGowan, Anup Aggarwal, Jason Ochoada, Jeanine Price, DongGeun Lee, Lei Yang, Francisca N. de Luna Vitorino, Sarah M. Young, Renee Dean, Joanna Lempiainen, Lauren Mascibroda, Josi Lott, Jamila Moore, Dixie Brewington, Paula Perez Sanchez, Suiping Zhou, Vishwajeeth Pagala, Yingxue Fu, Zuo-Fei Yuan, Anthony High, Benjamin Leslie, Vibhor Mishra, Sandi Radko-Juettner, Baranda Hansen, Shondra Pruett-Miller, Benjamin Garcia, Jeffery Klco, Madan Babu, Marcus Fischer, Martine F. Roussel, Zoran Rankovic, Charles G. Mullighan
• LB041 · PDF Decoding single-cell protein interactomes of CAR T cells with the Proximity Network Assay Filip Karlsson, Michele Simonetti, Christina Galonska, Hanna van Ooijen, Tomasz Kallas, Divya Thiagarajan, Maud Schweitzer, Ludvig Larsson, Vincent van Hoef, William Love, Jerell Aguila, Simon Fredriksson, Michael Forster
• LB042 · PDF Elucidating plasma bacterial and host derived metabolites unique to epithelial ovarian cancer Diane E. Mahoney, Ilce Medina-Meza
• LB044 · PDF A chemoproteomic photoaffinity platform(PAfBPP) enables target identification and mechanistic dissection of aristolochic acid-induced nephrotoxicity Nan Chen, Biwei Liu, Wenqi Meng

在完整检索应用中浏览本分会场 →